China's Pharmaceutical Capacity Remains Strong Despite COVID-Related Downturn
Researched by Industrial Info Resources (Sugar Land, Texas)--According to China's National Bureau of Statistics, in 2019, China's pharmaceutical capacity reached 2.769 million tons, with a year-over-year growth of 20.2%. In 2020, capacity was 2.734 million tons, a slight downturn attributed to the COVID-19 pandemic. The annual output of China's active pharmaceutical ingredients (APIs) stabilized at about 2.5 million tons.
The types of APIs on the Chinese market are mainly concentrated on vitamins, antibiotics, analgesics and corticosteroids. China is the world's largest vitamin production and export country, mainly because the price there is 30% to 40% lower than the international average price, and analgesics such as citric acid have now become China's second-largest product.
Industrial Info is tracking 19 vitamin projects in China, worth $1.43 billion. Click here for a list, and see graph below for project spending by company.